IMMY’s Post

Genes & GLPs - Nature Versus Pharma With GLP-1 RA (glucagon-like peptide-1 receptor agonist) medications making headlines as 'game-changing' for weight loss. And with trials taking place for cardiovascular disease and neurodegenerative conditions hope is growing and hype is building. But GLPs are a natural part of our biology. So do we really need drugs to mimic them. This webinar will explore mechanisms, and gene-nutrient interactions to support GLP function naturally, and without side effects. Live from 7pm, Monday 29th April. Recording available to pre registrants. Register Free at: https://lnkd.in/dj5WMMRK #weightloss #wegovy #GLP #semaglutide #nutrigenomics #metabolichealth #healthspan

Biomarker subanalysis of a phase 3 RCT of SC Abatacept in 219 polyarticular JIA pts. Lower baseline levels of S100A8/9 & S100A12 predicted better response (JIA-ACR90 2.5) at 16 mos. Decr in S100A8/9 & S100A12 @4mos was >50% among responders

#Article Rapid Detection of Pathogens in Wound Exudate via Nucleic Acid Lateral Flow Immunoassay by Anna Brunauer, René D. Verboket, Daniel M. Kainz, Felix von Stetten and Susanna M. Früh https://lnkd.in/ePhdVZ2c MDPI The University of Freiburg #immunoassay #pointofcare #nucleicacid #openaccess #Abstract The rapid detection of pathogens in infected wounds can significantly improve the clinical outcome. Wound exudate, which can be collected in a non-invasive way, offers an attractive sample material for the detection of pathogens at the point-of-care (POC). Here, we report the development of a nucleic acid lateral flow immunoassay for direct detection of isothermally amplified DNA combined with fast sample preparation. The streamlined protocol was evaluated using human wound exudate spiked with the opportunistic pathogen Pseudomonas aeruginosa that cause severe health issues upon wound colonization. A detection limit of 2.1 × 105 CFU per mL of wound fluid was achieved, and no cross-reaction with other pathogens was observed. Furthermore, we integrated an internal amplification control that excludes false negative results and, in combination with the flow control, ensures the validity of the test result. The paper-based approach with only three simple hands-on steps has a turn-around time of less than 30 min and covers the complete analytical process chain from sample to answer. This newly developed workflow for wound fluid diagnostics has tremendous potential for reliable pathogen POC testing and subsequent target-oriented therapy.

Amoy Diagnostics (SZSE:300685) announced that its AmoyDx® FGFR2 Break-apart FISH Probe Kit has been approved as a companion diagnostic (CDx) for Eisai Co., Ltd.'s innovative targeted therapy, Tasurgratinib, in Japan. This approval represents a significant milestone in precision oncology, expanding treatment options for biliary tract cancer patients with FGFR2 gene fusions. Dr. Li-Mou Zheng, Founder and Chairman of AmoyDx, commented, “We are thrilled with the approval of our FGFR2 Break-apart FISH Probe Kit as a companion diagnostic for Eisai's Tasurgratinib. AmoyDx and Eisai have collaboratively developed this FISH kit in parallel with the clinical development of Tasurgratinib in cholangiocarcinoma. This collaboration underscores our commitment to breaking barriers to precision medicine and enhancing cancer care. We believe that this approval will significantly impact the treatment landscape for biliary tract cancer patients with FGFR2 gene fusions in Japan.” #PrecisionMedicine #Oncology #CancerCare #FGFR2 #CompanionDiagnostic #Tasurgratinib #BiliaryTractCancer #ClinicalDevelopment #MedicalInnovation #QimingPortfolio #QimingHealthcare

#Researchers, AGR2 (anterior gradient 2) is member of the disulfide-isomerase family with an intracellular role in protein folding and transport. However, it is also secreted as a functional extracellular protein. How would you propose to study its mode of action by distinguishing between its intracellular and secreted functions in the progression of lung fibrosis? Learn more on #opnMe and collaborate with us to access funding https://lnkd.in/e3YbJ_uY

For patients with primary biliary cholangitis, more receiving the peroxisome proliferator-activated receptor delta (PPARδ) aganist seladelpar have a biochemical response and alkaline phosphatase normalization #CheckRare #RareDisease #PBC https://lnkd.in/gWmvNTT2

Through our collaborative partner the Biologic Association, IOF Members can register for a PRP Characterization and Dosing Webinar TOMORROW featuring Don Buford, MD, IOF president-elect. Learn about PRP cell counting and how to transform hematology data into tangible clinical insights at the point of care. Register here: https://bit.ly/48zi9La Objectives: 1) Review what data to look for (and look past!) when reviewing cell data 2) Interpret minimum standards for PRP Dose, Purity, Efficiency and Activation (DEPA) 3) Discuss the pearls and pitfalls of running hemocytometers & their maintenance at the POC 4) Establish how to integrate this cellular data into PRO registries resulting in meaningful interpretation of clinical outcomes

Increasingly promising clinical outcomes of obesity treatments inspired Eurofins Discovery to create a new panel -- obesityLITE – featuring 25 functional GPCR assays proven successful in targeting key metabolic targets. Benefits include: ·  Accelerated assessment of multiple receptor targeted therapies for potency, selectivity, and mechanistic activity ·  GPCR β-arrestin or second messenger assays to identify compound bias ·  Dose response profiling of small and large molecule libraries ·  Flexible screening solutions allows combining counterscreen assays with panel runs ·  Incredible introductory panel pricing Eurofins Discovery LeadHunter® Services deliver a robust platform that offers the flexibility to create personalized screening solutions, by combining panel screen with ad-hoc counterscreen assays from a comprehensive set of GPCR assay services.   Speak with an expert about your program: https://lnkd.in/gC7mAsMK   Learn more: https://lnkd.in/gc863RkJ #drugdiscovery #eurofins

Diazyme Now Offers a Calprotectin Assay! A biomarker for the diagnosis of irritable bowel disease (IBD) for your chemistry analyzer, and Diazyme c270 chemistry analyzer. Calprotectin is a calcium binding protein present in the neutrophil cytoplasm, representing over 60% of cytosolic proteins. Consequently, fecal calprotectin concentration may be related to inflammation of the bowel mucosa in IBD. Encouraging data have been published about the clinical efficacy of FC for monitoring disease activity, response to treatment and relapse. The Diazyme Calprotectin Assay is immunoturbidimetric assay used for the quantitative measurement of human fecal calprotectin in human stool. For in vitro diagnostic use only. Learn More about Diazyme’s Calprotectin Assay today! https://bit.ly/3fewnvx #CalprotecctinAssay #IBDSolutions #IBS #IBD #ClinicalChemistry

We would like to share with you a summary of data from a study that focused on comparing the antibody response to individual Borrelia antigens in three groups of patients with erythema migrans, neuroborreliosis and late Lyme disease. TestLine Clinical Diagnostics s.r.o. serological diagnostic kits were used for the study, where the ELISA and CLIA methods were compared, and the MBA (Microblot-Array) method was used as a confirmatory method. The results demonstrated a high agreement between both CLIA and ELISA screening methods: - 97,4 % (IgM) - 93,3 % (IgG) The comparison shows that the new generation of CLIA serological methods has the same sensitivity and specificity as ELISA, and the results also agree with the MBA confirmatory method. The results of the development of antibodies in various manifestations of Lyme disease can be useful for the diagnosis of the disease and subsequent treatment of the patient. Click here https://bit.ly/3TTd5fr for the full poster. Do you have any questions? Email us at clia@biovendor.group or contact our colleague Zuzana Nekorancová. #BioVendorGroup #borreliosis #lymedisease #biotechnology #diagnostics #laboratory